0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GCGR

GCGR

Brief Information

Name:Glucagon receptor
Target Synonym:GL-R,GCGR,Glucagon Receptor,GGR,Receptors, Glucagon
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GCR-M5254 Mouse Mouse GCGR / Glucagon receptor Protein, Fc Tag
GCR-M5254-structure
GCR-M5254-sds
GCR-H52H3 Human Human GCGR / Glucagon receptor Protein, His Tag (MALS verified)
GCR-H52H3-structure
GCR-H52H3-sds

Part of Bioactivity data

GCR-H52H3-ELISA
Human GCGR, His Tag (Cat. No. ) MALS images

The purity of Human GCGR, His Tag(Cat. No. GCR-H52H3) was more than 85% and the molecular weight of this protein is around 23-33 kDa verified by SEC-MALS.

  • Background
    G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

Glucagon R, GCGR,Glucagon receptor

Background

G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Glucagon (rDNA origin, Lilly) Approved Eli Lilly And Company Glucagon United States Hypoglycemia Eli Lilly And Company 1998-09-11 Diabetes Mellitus, Type 1; Hypoglycemia Details
Glucagon (Xeris Pharmaceuticals) Approved Xeris Pharmaceuticals Gvoke United States Hypoglycemia Xeris Pharmaceuticals Inc 1960-01-01 Hypoglycemia; Hyperinsulinism Details
Glucagon (rDNA origin, Novo Nordisk) GL-G Approved Novo Nordisk A/S GlucaGen, Glucagon G Japan Hypoglycemia Novo Nordisk A/S 1998-06-22 Hypoglycemia Details
Glucagon intranasal (Eli Lilly/Locemia Solutions) AMG504-1; LY-900018 Approved Amg Medical, Locemia Solutions Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus Details
Dasiglucagon ZP-GA-1; ZP-4207 Approved Zealand Pharma A/S ZEGALOGUE United States Hypoglycemia Zealand Pharma, Zealand Pharma A/S 2021-03-22 Diabetes Mellitus, Type 1; Congenital Hyperinsulinism; Hypoglycemia; Glucose Metabolism Disorders Details
Glucagon MP-123456B Approved Eli Lilly And Company Baqsimi, Ogluo EU Diabetes Mellitus Eli Lilly Nederland Bv 1960-11-14 Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
HM-15136 HM-15136 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Congenital Hyperinsulinism; Diabetes Mellitus, Type 2; Hyperinsulinism Details
PRT-003 PRT-003 Phase 1 Clinical Particle Therapeutics Details
SAR-441255 SAR-441255 Phase 1 Clinical Sanofi Diabetes Mellitus, Type 2; Obesity; Overweight Details
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) Phase 1 Clinical Translational Research Institute For Metabolism And Diabetes Obesity Details
NN-9513 (Novo Nordisk) Phase 1 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus Details
Isosteviol ISV; STX-03 Phase 2 Clinical Stevia Pharma Diabetes Mellitus, Type 2 Details
IONIS-GCGRRx ISISGCGRRx; ISIS-449884; IONIS-GCGRRx Phase 2 Clinical Ionis Diabetes Mellitus, Type 2 Details
volagidemab AMG-477; REMD-477 Phase 2 Clinical Amgen Inc Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus Details
BioChaperone Glucagon BC Glucagon Phase 1 Clinical Adocia Diabetes Mellitus, Type 1; Hypoglycemia Details
NN-9277 NN-9277; NNC-9204-1177 Phase 1 Clinical Novo Nordisk A/S Obesity; Overweight Details
Oxyntomodulin (Xenetic Biosciences) Phase 2 Clinical Pharmsynthez, Xenetic Biosciences Diabetes Mellitus, Type 2; Obesity Details
Pegapamodutide TT-401; OPK-88003; LY-2944876; WG4ID2U7FT Phase 2 Clinical Eli Lilly And Company Diabetes Mellitus, Type 2; Obesity Details
LGD-6972 LGD-6972; MB-11262; RVT-1502 Phase 2 Clinical Ligand Pharmaceuticals Inc Diabetes Mellitus, Type 2 Details
ZP-2929 ZP-2929 Phase 1 Clinical Zealand Pharma A/S Diabetes Mellitus, Type 2; Obesity Details
PRT-001 PRT-001 Phase 3 Clinical Particle Therapeutics Hypoglycemia Details
Cotadutide MEDI-0382 Phase 2 Clinical Medimmune Llc Diabetes Mellitus, Type 2; Renal Insufficiency; Non-alcoholic Fatty Liver Disease; Obesity; Renal Insufficiency, Chronic Details
HM-15211 HM-15211 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Non-alcoholic Fatty Liver Disease; Obesity Details
LY-3305677 OXM-3; IBI-362; LY-3305677 Phase 2 Clinical Eli Lilly And Company Diabetes Mellitus, Type 2; Obesity; Overweight Details
BI-456906 BI-456906 Phase 2 Clinical Zealand Pharma A/S Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight Details
Efinopegdutide JNJ-5111; HM-12525A; JNJ-64565111 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Kidney Failure, Chronic Details

This web search service is supported by Google Inc.

totop